Bio Green Med Solution (BGMS) AI Stock Analysis

• Market Cap: $6.47M
• Dividend Yield: 10.27%
• Average Volume (3M): 473.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 9.46%
• EPS Growth: 96.85%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -1.31
• Shares Outstanding: 4,900,142
• 10 Day Avg. Volume: 1,252,948
• 30 Day Avg. Volume: 473,939
• PEG Ratio: <0.01
• Price to Book (P/B): -0.06
• Price to Sales (P/S): 3.12
• P/FCF Ratio: -0.02
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: -15.89
• Enterprise Value/Gross Profit: -80.46
• Enterprise Value/Ebitda: 0.14
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.50 ▲(3.45% Upside)

The score is primarily constrained by weak financial performance: very small revenue, deeply negative margins, and substantial ongoing cash burn despite an improved, low-debt balance sheet. Technicals also remain unfavorable with price below key moving averages and negative MACD. Valuation is mixed—an unusually high dividend yield provides some support, but the negative P/E underscores continued losses.

Bio Green Med Solution Business Overview & Revenue Model

Company Description

A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.

How the Company Makes Money

Cyclacel Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company’s revenue model is centered around licensing agreements, collaborations, and strategic partnerships with other pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on sales of successfully developed products. Additionally, Cyclacel may receive funding from government grants and research collaborations, which support their clinical trials and research initiatives. As a clinical-stage company, significant revenue generation typically occurs post-commercialization of their drug candidates.

Bio Green Med Solution Financial Statement Overview

Summary

Revenue rebounded to $81K TTM but remains extremely small, while profitability is deeply negative (net margin ~-67% and EBIT/EBITDA margins near -114%). Cash burn is heavy with TTM operating cash flow and free cash flow around -$6.1M, implying continued funding dependence. The balance sheet is a relative bright spot with very low leverage and improved equity (~$7.1M), reducing near-term solvency risk but not offsetting persistent operating losses.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply to $81K (up materially versus the prior annual period), but the base remains extremely small. Profitability is deeply negative with a TTM net margin of about -67% and EBIT/EBITDA margins near -114%, indicating operating costs are far out of line with current revenue. While losses narrowed versus 2023/2024, the company remains far from breakeven.

Balance Sheet

Leverage is very low (TTM debt-to-equity ~0.00 with only ~$5K of debt), which reduces near-term balance sheet risk. Equity improved meaningfully from negative in 2024 to ~$7.1M in TTM, suggesting recapitalization or balance sheet repair. However, returns remain weak (TTM return on equity is deeply negative), reflecting continued losses and limited evidence yet that the stronger equity base is translating into sustainable profitability.

Cash Flow

Cash generation is materially negative: TTM operating cash flow and free cash flow are both about -$6.1M, and free cash flow declined further versus the prior period. Cash burn remains large relative to the current revenue scale, increasing ongoing funding dependence. A positive note is that free cash flow roughly tracks net income (free cash flow to net income ~1.0), but both are significantly negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	81.00K	43.00K	420.00K	0.00	0.00	0.00
Gross Profit	16.00K	43.00K	420.00K	0.00	0.00	-20.00K
EBITDA	-9.23M	-12.00M	-25.42M	-27.62M	-22.35M	-9.66M
Net Income	-5.44M	-11.21M	-22.55M	-21.20M	-18.46M	-8.45M
Balance Sheet
Total Assets	8.16M	4.09M	8.80M	28.05M	43.14M	36.80M
Cash, Cash Equivalents and Short-Term Investments	3.84M	3.14M	3.38M	18.34M	36.56M	33.41M
Total Debt	5.00K	0.00	37.00K	106.00K	30.00K	1.06M
Total Liabilities	1.06M	6.27M	8.20M	7.62M	5.44M	3.54M
Stockholders Equity	7.10M	-2.17M	607.00K	20.43M	37.69M	33.26M
Cash Flow
Free Cash Flow	-6.09M	-7.99M	-16.12M	-20.83M	-18.57M	-8.03M
Operating Cash Flow	-6.09M	-7.99M	-16.11M	-20.83M	-18.54M	-7.93M
Investing Cash Flow	0.00	0.00	-6.00K	-7.00K	-27.00K	-96.00K
Financing Cash Flow	7.14M	7.82M	848.00K	3.00M	21.74M	29.50M

Bio Green Med Solution Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of 1.45 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.44, and below the 200-day MA of 13.20, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.34 is Neutral, neither overbought nor oversold. The STOCH value of 23.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.

Bio Green Med Solution Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEUP	52 Neutral	$22.53M	-0.18	-59.91%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNTX	48 Neutral	$36.01M	-0.52	-83.28%	―	―	15.35%
BGMS	47 Neutral	$6.47M	-0.02	-226.28%	10.27%	9.46%	96.85%
BJDX	46 Neutral	$1.49M	-0.03	-126.20%	―	―	97.70%
BDRX	41 Neutral	$1.33M	-0.03	-60.37%	―	-100.00%	86.75%

Bio Green Med Solution Corporate Events

Bio Green Med Solution Declares Quarterly Preferred Stock Dividend

On January 12, 2026, Bio Green Med Solution, Inc. announced that its board of directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, payable on February 1, 2026, to holders of record as of January 22, 2026. The move provides direct cash returns to preferred shareholders and signals the company’s continued commitment to servicing its preferred equity capital structure.

The most recent analyst rating on (BGMS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bio Green Med Solution stock, see the BGMS Stock Forecast page.

Bio Green Med Solution Reports Q3 Financial Results

On November 13, 2025, Bio Green Med Solution reported its third-quarter financial results, highlighting several strategic moves to strengthen its market position. Key developments included a reverse stock split in July, a warrant exchange agreement in September, and the acquisition of Fitters Sdn. Bhd., which became a wholly-owned subsidiary. The company also sold assets related to Plogosertib, a cancer treatment, and declared a cash dividend on its preferred stock. Financially, the company reported a net loss of $1.0 million for the quarter, with cash reserves expected to support operations into early 2026.

Bio Green Med Solution’s Warrant Exchange Agreement

On November 5, 2025, Bio Green Med Solution, Inc. entered into a Warrant Exchange Agreement with accredited investors to exchange existing warrants for 1,402,605 shares of common stock. This move, leveraging an exemption under the Securities Act of 1933, is poised to impact the company’s financial structure and stakeholder equity without requiring registration.